In the haplo-HCT setting performed through the infusion of positively selected CD34+ cells, the first emergence of fully functioning, KIR alloreactive NK cells from hematopoietic progenitors may require at least 6–8 weeks, and therefore the benefit offered by their anti-leukemia effect is delayed (168–171). The gene discussed is KIR3DL1; the disease is leukemia.